Axplora has recently disclosed a substantial investment in its Vizag site located in India, aiming to expand production capacity and fortify supply chain resilience. This decision comes on the heels of the successful 2025 USFDA inspections at both of Axplora’s Indian manufacturing units, Vizag and Chennai, which are integral parts of its PharmaZell Business Unit. The expansion initiative at Vizag is set to boost output levels and generate fresh employment opportunities within the region.
The investment made by Axplora not only amplifies production capabilities but also aligns with the company’s sustainability objectives by promoting streamlined, vertically integrated production processes at a singular location. Emphasizing the significance of this investment, Martin Meeson, the CEO of Axplora, highlighted how this strategic move enhances their operational efficiency and growth-oriented approach, positioning them to deliver top-notch, scalable solutions to their global clientele.
Following the USFDA inspections in 2025, both the Vizag and Chennai sites received a Voluntary Action Indicated (VAI) classification, a testament to their adherence to stringent quality and regulatory standards. The inspection report for the Chennai facility specifically lauded various aspects of operational excellence, including robust implementation of current Good Manufacturing Practices (cGMP), efficient document management systems, and the strict maintenance of site hygiene and upkeep standards.
Axplora, formed through the amalgamation of PharmaZell, Farmabios, and Novasep CDMO, serves as a manufacturing partner for more than 900 pharmaceutical and biotech companies globally. With a network comprising 9 API manufacturing sites in Europe and India, Axplora offers multi-site capacity to cater to the diverse needs of its partners across the pharmaceutical landscape.
Key Takeaways:
– Axplora’s investment of €6.5 million in the Vizag facility underscores its commitment to enhancing production capabilities and fortifying its global supply chain.
– The successful USFDA inspections in 2025 at both the Vizag and Chennai sites, with a VAI classification, affirm Axplora’s dedication to maintaining high-quality standards and regulatory compliance.
– As a pivotal manufacturing partner to numerous pharmaceutical and biotech firms worldwide, Axplora’s multi-site capacity across Europe and India positions it as a key player in the industry.
– The expansion project at Vizag not only aims to increase output but also focuses on sustainability goals by streamlining production processes at a single site, showcasing Axplora’s dedication to operational excellence.
Tags: regulatory, biotech
Read more on medicaldialogues.in